Related Experiment Video
Updated: Aug 23, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts
Bryce D Beseth1, Robert B Cameron, Pamela Leland
1Section of General Thoracic Surgery, University of California, Los Angeles, California 90095-1741, USA.
Background:
Malignant pleural mesothelioma (MPM) is an uncommon but highly fatal neoplasm for which only limited treatment is available.
Methods:
Immunohistochemical analysis was used to determine the expression of interleukin-4 receptors (IL-4R) on mesothelioma cell lines and resected mesothelioma tumors. Radioreceptor binding assays were used to show that these IL-4R were high-affinity receptors. Previously, we had shown that a chimeric protein composed of a circularly permuted IL-4 molecule fused to a truncated form of Pseudomonas exotoxin A, IL-4(38-37)-PE38KDEL, could be used to kill IL-4R-bearing tumor cells in vitro. The toxicity of this molecule to mesothelioma cell lines was tested using a protein synthesis inhibition assay. A human mesothelioma xenograft model was then developed to assess the efficacy of this molecule in vivo.
Results:
All MPM cell lines tested were found to express high-affinity cell-surface IL-4R. Immunohistochemical analysis of resected mesothelioma tumor specimens from 13 patients revealed that all tumors expressed moderate-to-high levels of IL-4R. Coculture of malignant mesothelioma cell lines with IL-4(38-37)-PE38KDEL resulted in a dose-dependent inhibition of tumor cell protein synthesis through an interaction with cell-surface IL-4R. In a nude mouse xenograft model of human MPM, intratumoral administration of IL-4(38-37)-PE38KDEL mediated a dose-dependent decrease in tumor volume and a dose-dependent increase in survival.
Conclusions:
The chimeric protein, IL-4(38-37)-PE38KDEL, has potent antitumor effects against MPM both in vitro and in vivo.
Insights
A novel chimeric protein, IL-4(38-37)-PE38KDEL, shows potent antitumor effects against malignant pleural mesothelioma (MPM). This targeted therapy effectively reduces tumor volume and increases survival in preclinical models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with limited therapeutic options.
- Interleukin-4 receptors (IL-4R) are implicated in MPM cell growth and survival.
Purpose of the Study:
- To evaluate the expression of IL-4R on MPM cells.
- To assess the efficacy of a novel chimeric protein, IL-4(38-37)-PE38KDEL, targeting IL-4R for MPM treatment.
Main Methods:
- Immunohistochemistry and radioreceptor binding assays to characterize IL-4R expression and affinity.
- In vitro protein synthesis inhibition assays to determine cytotoxicity.
- Nude mouse xenograft model to evaluate in vivo antitumor efficacy.
Main Results:
- MPM cell lines and patient tumors consistently expressed high-affinity IL-4R.
- IL-4(38-37)-PE38KDEL demonstrated dose-dependent inhibition of protein synthesis in MPM cells.
- Intratumoral administration of the chimeric protein reduced tumor volume and improved survival in a xenograft model.
Conclusions:
- The chimeric protein IL-4(38-37)-PE38KDEL exhibits significant antitumor activity against MPM.
- Targeting IL-4R with this novel agent represents a promising therapeutic strategy for MPM.
